Preventive and/or therapeutic method for systemic lupus erythematosus comprising anti-IL-6 receptor antibody administration

• US 20090022719A1
• Filed: 09/16/2008
• Published: 01/22/2009
• Est. Priority Date: 08/15/1997
• Status: Abandoned Application

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Mihara, Masahiko, Ohsugi, Yoshiyuki
• Application Number:
  US12/232,341
• Publication Number:
  US 20090022719A1
• Time in Patent Office: Days
• US Class Current: 424/133.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

A preventive and/or therapeutic agent for systemic lupus erythematosus comprising an anti-interleukin-6 (IL-6) receptor antibody as an active ingredient.

Claims

1-12. -12. (canceled)

13. A method for treating lupus nephritis in systemic lupus erythematosus in a patient suffering from lupus nephritis comprising administering a therapeutically effective amount of an anti-interleukin-6 (IL-6) receptor antibody to said patient.

14. The method according to claim 13, wherein the anti-IL-6 receptor antibody is a monoclonal anti-IL-6 receptor antibody.

15. The method according to claim 13, wherein the anti-IL-6 receptor antibody is a recombinant anti-IL-6 receptor antibody.

16. The method according to claim 13, wherein the anti-IL-6 receptor antibody is a chimeric or humanized anti-IL-6 receptor antibody.

17. The method according to claim 13, wherein the anti-IL-6 receptor antibody is a humanized PM-1 antibody.